Advertisement

Topics

Hair Repigmentation Observed in NSCLC Patients Receiving PD-L1 Therapy

05:00 EDT 11 Aug 2017 | OncoTherapy Network

Researchers in Spain discovered a strange side effect of PD-L1 immunotherapy in some NSCLC patients—hair repigmentation—that may be a good response marker for this treatment.

Original Article: Hair Repigmentation Observed in NSCLC Patients Receiving PD-L1 Therapy

NEXT ARTICLE

More From BioPortfolio on "Hair Repigmentation Observed in NSCLC Patients Receiving PD-L1 Therapy"

Quick Search
Advertisement
 

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...